Loading…
← CockpitCompetitor Analysis › GYRE Gyre Therapeutics IncOpen in the cockpit ↗

Gyre Therapeutics IncGYRECompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 12
Mkt cap
$500M
US dollars, full cap
Free float
22%
of shares outstanding
$/day
$1.15M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-28.8 pp
WACC 17.7%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · USD$4.34
1D-4.8%
1W+1.9%
1M-29.7%
3M-38.2%
6M-28.1%
YTD-38.5%
1Y-45.9%
ATR %10.2%
Beta1.58
52w lowhigh52.5% off high

What Gyre Therapeutics does

Employees: 625

Gyre Therapeutics at a glance

Size Gyre Therapeutics (GYRE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $500M, the 2669th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.34 on 18 Nov 2026.

Performance Over six months the shares fell 28.1%, against -18.4% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 13.5% over the last twelve months (peer median +9.4%); the operating margin is -18.1% (peer median 10.0%).

Valuation It trades at 4.0× enterprise value to sales against a peer median of 3.7× (10th most expensive of 20).

Capital Return on invested capital runs 28.8 points below its cost of capital (17.7% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 83GYRE 70
Six months, rebased to 100: Gyre Therapeutics against the median of its 20 peers (local-currency closes).

Gyre Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$122M$117M$106M$113M$102M
Revenue growth—+10%-7%+11%—
Gross profit$115M$111M$102M$109M$97.5M
EBITDA-$18.7M$14.0M$17.8M$20.3M$10.3M
Net income-$25.1M$5.03M$12.1M-$92.9M$2.30M
Free cash flow-$24.7M-$1.67M-$6.49M$17.4M$5.69M
Capital expenditure$2.68M$1.92M$3.13M$8.59M$5.00M
Total debt$3.01M$939,000$1.60M$409,000$613,000

Quarterly statements and history in the cockpit →

Gyre Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%603207600222GUJTHEMINDPTKNO600513003090AARTIDRUGS002107EGTX1666301277003020RGNXHNSA600624GYRE6-month return →1-month return →
Up and to the right = strong over both horizons. Gyre Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×25×50×75×603207600222GUJTHEMTKNO600513003090AARTIDRUGS002107EGTX1666300584300485688373HNSAGYRERevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Gyre Therapeutics is the large dot.

Gyre Therapeutics competitors and peer comparison

How Gyre Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Gyre Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureGYREPeer medianRank in peer set
1-month return-29.7%-2.1%lowest of 21
6-month return-28.1%-18.4%4th lowest of 21
Distance from 52-week high-52.5%-35.5%4th lowest of 21
Revenue growth (TTM)+13.5%+9.4%9th highest of 20
Operating margin-18.1%10.0%7th lowest of 20
EV / Sales4.0×3.7×10th most expensive of 20
ROIC minus cost of capital-28.8 pp-2.4 pp3rd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a

Questions

Which companies are Gyre Therapeutics's closest peers?
The cockpit's peer set: Shanghai Xiao Fang Pharmaceutical (603207.SS), Henan Taloph Pharmaceutical Stock (600222.SS), Gujarat Themis Biosyn (GUJTHEM.NS), Indaptus Therapeutics (INDP), Alpha Teknova (TKNO), Jiangsu Lianhuan Pharmaceutical (600513.SS), Daewoong (003090.KS), Aarti Drugs (AARTIDRUGS.NS).
Is Gyre Therapeutics expensive compared with its peers?
On ev / sales it trades at 4.0× against a peer median of 3.7×, 10th most expensive of 20 in its peer set.
How has Gyre Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -28.1% against -18.4% for the median peer; over one year -45.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.